Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK and safety study of RLYB212 in pregnant women at high risk for HPA-1a alloimmunization
NL-OMON59335Phase 2Completed
- Sponsor
- Rallybio
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RLYB212 in fetomaternal alloimmune thrombocytopenia (FMAIT), sponsored by Rallybio. Primary endpoints: Maternal pharmacokinetic parameters of RLYB212 and Maternal and fetal safety. Started Jan 2025; status: completed.
02
Drugs
RLYB212
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on NL-OMON59335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59335.